

ForPatients

by Roche

Geographic Atrophy

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Trial Status
Recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT05626114 GR44251

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT05626114 GR44251
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=50 Years

Healthy Volunteers
No
